Clinical Services
Phase I/IIa
Quotient Bioresearch has a strong heritage in First-In-Human (FIH) studies and can work with you to deliver differentiated, value added Phase I/IIa clinical trials. In January 2009 we were awarded Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA). This demonstrates our experience in and capabilities to conduct FIH trials for small molecules and biologics, an area in which we have more than 20 years’ experience. Read more
Drug Product Optimisation
Our drug product optimisation service combines our expertise in formulation, manufacturing, drug delivery and clinical studies into a single service. This service can be deployed alone or in combination. Read more.
14C Enabled Drug Development
Our unrivalled expertise in 14C radiolabelled drug delivery adds value to your early drug development programmes. We have long been at the forefront of this field, with extensive experience in ivMicrotracer™ and Phase 0 microdose studies.
Our unique Synthesis-to-Clinic™ integrated platform works to accelerate your drug development programme. Read more.
Contact us to find out more and to discuss your specific needs